LLY

1,031.07

-1.11%↓

JNJ

245.04

-0.21%↓

ABBV

226.71

-0.78%↓

NVS

167.17

+0.28%↑

MRK

122.88

-1.14%↓

LLY

1,031.07

-1.11%↓

JNJ

245.04

-0.21%↓

ABBV

226.71

-0.78%↓

NVS

167.17

+0.28%↑

MRK

122.88

-1.14%↓

LLY

1,031.07

-1.11%↓

JNJ

245.04

-0.21%↓

ABBV

226.71

-0.78%↓

NVS

167.17

+0.28%↑

MRK

122.88

-1.14%↓

LLY

1,031.07

-1.11%↓

JNJ

245.04

-0.21%↓

ABBV

226.71

-0.78%↓

NVS

167.17

+0.28%↑

MRK

122.88

-1.14%↓

LLY

1,031.07

-1.11%↓

JNJ

245.04

-0.21%↓

ABBV

226.71

-0.78%↓

NVS

167.17

+0.28%↑

MRK

122.88

-1.14%↓

Search

Quidel Corp

Abrir

23.43 11.89

Visão Geral

Variação de preço das ações

24h

Atual

Mín

21.34

Máximo

24.23

Indicadores-chave

By Trading Economics

Funcionários

6,600

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+45.12% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-285M

1.4B

Abertura anterior

11.54

Fecho anterior

23.43

Quidel Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de fev. de 2026, 23:07 UTC

Ganhos

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 de fev. de 2026, 23:01 UTC

Ganhos

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 de fev. de 2026, 22:59 UTC

Ganhos

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 de fev. de 2026, 22:42 UTC

Ganhos

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 de fev. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 de fev. de 2026, 23:46 UTC

Conversa de Mercado

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 de fev. de 2026, 23:36 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 de fev. de 2026, 23:30 UTC

Conversa de Mercado

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 de fev. de 2026, 23:20 UTC

Conversa de Mercado

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 de fev. de 2026, 23:20 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

24 de fev. de 2026, 23:16 UTC

Ganhos

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 de fev. de 2026, 23:13 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 de fev. de 2026, 23:12 UTC

Ganhos

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 de fev. de 2026, 23:10 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 de fev. de 2026, 23:10 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 de fev. de 2026, 23:08 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 de fev. de 2026, 23:07 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 de fev. de 2026, 22:52 UTC

Ganhos

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 de fev. de 2026, 22:46 UTC

Ganhos

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 de fev. de 2026, 22:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Receives New Bid From Paramount -- 3rd Update

24 de fev. de 2026, 22:29 UTC

Ganhos

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 de fev. de 2026, 22:28 UTC

Ganhos

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 de fev. de 2026, 22:27 UTC

Ganhos

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 de fev. de 2026, 22:27 UTC

Ganhos

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 de fev. de 2026, 22:25 UTC

Ganhos

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 de fev. de 2026, 22:24 UTC

Ganhos

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 de fev. de 2026, 22:23 UTC

Ganhos

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 de fev. de 2026, 22:22 UTC

Ganhos

Woolworths Interim Dividend 45 Australian Cents/Share

24 de fev. de 2026, 22:22 UTC

Ganhos

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 de fev. de 2026, 22:21 UTC

Ganhos

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Comparação entre Pares

Variação de preço

Quidel Corp Previsão

Preço-alvo

By TipRanks

45.12% parte superior

Previsão para 12 meses

Média 30.75 USD  45.12%

Máximo 38 USD

Mínimo 25 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Quidel Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

1

Comprar

3

Manter

1

Vender

Informação Financeira

$

Sobre Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat